title: Where do leukotriene modifiers fit in asthma management?
abstract: Effective asthma treatment requires long-term inflammation control. Patient adherence to corticosteroid treatment regimens remains problematic. Leukotriene modifiers, a newer drug class, add to the pharmacologic approaches to asthma management. Here, we review the role of leukotrienes in asthma pathogenesis and appropriate uses for leukotriene modifiers in asthma management.
authors: University of California, San Francisco, USA.
authors: Susan
authors: S
authors: Janson
authors: Stephen C
authors: SC
authors: Lazarus
mesh_terms: D000085:Acetates / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D015267:Churg-Strauss Syndrome / Q000139:chemically induced; D003521:Cyclopropanes; D005541:Forced Expiratory Volume; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D015289:Leukotrienes / Q000502:physiology; D048448:Phenylcarbamates; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D007211:Indoles; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D048448:Phenylcarbamates; D011804:Quinolines; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds; C093875:montelukast; C062735:zafirlukast